Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407160 · ClinicalTrials.gov registry record
A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients
A clinical trial, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- 21
- Enrollment target
NCT00407160: Completed study, sponsored by The University of Texas Medical Branch, Galveston.
NCT00407160 is a clinical trial that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00407160 has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
Comparison between Campath induction and monotherapy with Tacrolimus vs Thymoglobulin induction and triple drug maintenance using Tacrolimus, mycophenolate, and steroids.
Primary Outcome
Cumulative graft survival at 1 year
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-08 |
| Est. Completion | 2011-01 |
What the finished NCT00407160 record still lists
NCT00407160 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00407160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00407160 about?
NCT00407160 is a clinical study titled "A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients". Comparison between Campath induction and monotherapy with Tacrolimus vs Thymoglobulin induction and triple drug maintenance using Tacrolimus, mycophenolate, and steroids.
What is the current status of trial NCT00407160?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2004-08. Estimated completion is 2011-01.
Who is sponsoring clinical trial NCT00407160?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia